000			01394 a2200421 4500
005			20250518014918.0
264		0	_c20201007
008			202010s 0 0 eng d
022			_a1097-0347
024	7		_a10.1002/hed.25477 _2doi
040			_aNLM _beng _cNLM
100	1		_aCabo Beltran, Olga Rodriguez
245	0	0	_aMVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis. _h[electronic resource]
260			_bHead & neck _c03 2019
300			_a657-665 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aChild
650	0	4	_aChild, Preschool
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aLaryngoscopy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPapillomavirus Infections _xpathology
650	0	4	_aRespiratory Tract Infections _xpathology
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
650	0	4	_aVaccines, DNA
650	0	4	_aViral Vaccines
650	0	4	_aYoung Adult
700	1		_aRosales Ledezma, Ricardo
773	0		_tHead & neck _gvol. 41 _gno. 3 _gp. 657-665
856	4	0	_uhttps://doi.org/10.1002/hed.25477 _zAvailable from publisher's website
999			_c29216937 _d29216937